Leone D. Patterson

CIK: 0001233539

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

IRLA

IRulya Therapeutics Inc.

Director

NKTX

Nkarta, Inc.

Director

KLRS

Kalaris Therapeutics, Inc.

Director

ZYME

Zymeworks Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

NKTX
Nkarta, Inc.
Jun 10, 2026
Award(A)
Stock Option (right to buy)
Direct
37K shares-
KLRS
Kalaris Therapeutics, Inc.
Jun 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
9K shares-
ZYME
Zymeworks Inc.
Jan 6, 2026
Award(A)
Direct
459 shares at avg. $10.55$5K
NKTX
Nkarta, Inc.
Jun 5, 2025
Award(A)
Stock Option (right to buy)
Direct
46K shares-
KLRS
Kalaris Therapeutics, Inc.
Apr 10, 2025
Award(A)
Stock Option (Right to Buy)
Direct
18K shares-
ZYME
Zymeworks Inc.
Jan 10, 2025
Award(A)
Stock Option (Right to Buy)
Direct
79K shares-
ZYME
Zymeworks Inc.
Jan 10, 2025
Award(A)
Restricted Stock Unit
Direct
53K shares-
ZYME
Zymeworks Inc.
Sep 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
360K shares-

		Type	Shares	Price		Ownership
Jun 10, 2026	NKTX Nkarta, Inc.	Award(A) Stock Option (right to buy)	37,000	-	-	Direct
Jun 3, 2026	KLRS Kalaris Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	9,000	-	-	Direct
Jan 6, 2026	ZYME Zymeworks Inc.	Award(A)	459	$10.55	$4,842	Direct
Jun 5, 2025	NKTX Nkarta, Inc.	Award(A) Stock Option (right to buy)	46,000	-	-	Direct
Apr 10, 2025	KLRS Kalaris Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	18,000	-	-	Direct
Jan 10, 2025	ZYME Zymeworks Inc.	Award(A) Stock Option (Right to Buy)	79,000	-	-	Direct
Jan 10, 2025	ZYME Zymeworks Inc.	Award(A) Restricted Stock Unit	53,000	-	-	Direct
Sep 1, 2024	ZYME Zymeworks Inc.	Award(A) Stock Option (Right to Buy)	360,000	-	-	Direct

1-8 of 8 transactions

About PATTERSON LEONE D

PATTERSON LEONE D (SEC CIK 0001233539) files insider reports with the SEC as Director of IRulya Therapeutics Inc. (IRLA), Director of Nkarta, Inc. (NKTX) and Director of Kalaris Therapeutics, Inc. (KLRS). Signal8 also holds filings tied to 1 other company.

Signal8 holds 10 ownership filings by PATTERSON LEONE D (3 Form 3, 7 Form 4), filed between Sep 3, 2024 and Oct 19, 2026. Those filings report 8 transactions, from Sep 1, 2024 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on PATTERSON LEONE D's filings is in NEW HAVEN, CT.

Recent filings by PATTERSON LEONE D

Jun 10, 2026: Grant or award of NKTX derivative securities (Form 4, code A).
Jun 3, 2026: Grant or award of KLRS derivative securities (Form 4, code A).
Jan 6, 2026: Grant or award of ZYME shares (Form 4, code A).
Jun 5, 2025: Grant or award of NKTX derivative securities (Form 4, code A).
Apr 10, 2025: Grant or award of KLRS derivative securities (Form 4, code A).

Other insiders filing for IRulya Therapeutics Inc. (IRLA)

Bonuccelli Catherine M., Director
Valentine James Elwood, Director
Wise John Drayton, Director
Militello John, Chief Financial Officer
Fandrick Keith R., Chief Operating Officer

How to read Form 4 transaction codes